{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T20:47:37Z","timestamp":1781988457711,"version":"3.54.5"},"reference-count":28,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2003,8,15]]},"abstract":"<jats:p> Purpose: Recombinant human thrombopoietin (rhTPO) increases platelets, and the peak response of rhTPO is delayed and is, therefore, not uniformly effective when administered after chemotherapy. The purpose of this study was to identify an effective schedule of rhTPO to best attenuate early thrombocytopenia. <\/jats:p><jats:p> Patients and Methods: Cohorts of six patients with sarcoma (66 assessable patients) were treated sequentially with doxorubicin and ifosfamide (AI), with rhTPO by a fixed dose and varying schedules being administered before and\/or after chemotherapy in cycle 2 and subsequent cycles. Cycle 1 without rhTPO served as an internal control. <\/jats:p><jats:p> Results: AI causes cumulative thrombocytopenia. The platelet nadir in cycle 2 was higher than in cycle 1 (mean nadir \u00b1 SEM, 119 \u00b1 12 \u00d7 10<jats:sup>3<\/jats:sup>\/\u03bcL v 80 \u00b1 7 \u00d7 10<jats:sup>3<\/jats:sup>\/\u03bcL, respectively; P &lt; .001) in 24 (80%) of the 30 patients (P &lt; .001) in whom rhTPO (1.2 \u03bcg\/kg) was administered starting from 5 days before chemotherapy (pre\/postdoses, three\/one or one\/one) compared with only four (17%) of 24 patients given rhTPO by other schedules (pre\/postdoses, two\/two, one\/three, zero\/four, or four\/zero) and none of 15 historical control patients. The need for platelet transfusions in four cycles was significantly lower (13 [11%] of 114 cycles, P &lt; .001) in patients who received rhTPO from day \u22125 (pre\/post doses, three\/one or one\/one) compared with patients who received rhTPO at later time points (28 [47%] of 60 cycles). Bone marrow megakaryocytes increased markedly (four-fold) before chemotherapy with predosing rhTPO and remained elevated (two-fold) after chemotherapy, which may explain the possible mechanism for response. One patient developed subclavian vein thrombosis, and no patients developed neutralizing antibodies to rhTPO. <\/jats:p><jats:p> Conclusion: These results demonstrate the importance of timing of rhTPO in relation to chemotherapy and indicate that, by optimizing the timing, only two doses of rhTPO (one before and one after chemotherapy) were required to significantly reduce the severity of chemotherapy-related early thrombocytopenia. <\/jats:p>","DOI":"10.1200\/jco.2003.08.003","type":"journal-article","created":{"date-parts":[[2003,8,14]],"date-time":"2003-08-14T22:53:56Z","timestamp":1060901636000},"page":"3158-3167","source":"Crossref","is-referenced-by-count":59,"title":["Importance of Predosing of Recombinant Human Thrombopoietin to Reduce Chemotherapy-Induced Early Thrombocytopenia"],"prefix":"10.1200","volume":"21","author":[{"given":"Saroj","family":"Vadhan-Raj","sequence":"first","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Sarcoma Medical Oncology, Hematopathology, and Biostatistics, the University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Microbiology and Immunology, the Walther Oncology Center and the Walther Cancer Institute, Indiana University School of Medicine, Indianapolis, IN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyaskumar","family":"Patel","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Sarcoma Medical Oncology, Hematopathology, and Biostatistics, the University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Microbiology and Immunology, the Walther Oncology Center and the Walther Cancer Institute, Indiana University School of Medicine, Indianapolis, IN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Bueso-Ramos","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Sarcoma Medical Oncology, Hematopathology, and Biostatistics, the University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Microbiology and Immunology, the Walther Oncology Center and the Walther Cancer Institute, Indiana University School of Medicine, Indianapolis, IN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody","family":"Folloder","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Sarcoma Medical Oncology, Hematopathology, and Biostatistics, the University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Microbiology and Immunology, the Walther Oncology Center and the Walther Cancer Institute, Indiana University School of Medicine, Indianapolis, IN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Papadopolous","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Sarcoma Medical Oncology, Hematopathology, and Biostatistics, the University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Microbiology and Immunology, the Walther Oncology Center and the Walther Cancer Institute, Indiana University School of Medicine, Indianapolis, IN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Burgess","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Sarcoma Medical Oncology, Hematopathology, and Biostatistics, the University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Microbiology and Immunology, the Walther Oncology Center and the Walther Cancer Institute, Indiana University School of Medicine, Indianapolis, IN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyle D.","family":"Broemeling","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Sarcoma Medical Oncology, Hematopathology, and Biostatistics, the University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Microbiology and Immunology, the Walther Oncology Center and the Walther Cancer Institute, Indiana University School of Medicine, Indianapolis, IN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hal E.","family":"Broxmeyer","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Sarcoma Medical Oncology, Hematopathology, and Biostatistics, the University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Microbiology and Immunology, the Walther Oncology Center and the Walther Cancer Institute, Indiana University School of Medicine, Indianapolis, IN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Benjamin","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Sarcoma Medical Oncology, Hematopathology, and Biostatistics, the University of Texas M.D. Anderson Cancer Center, Houston, TX; and the Department of Microbiology and Immunology, the Walther Oncology Center and the Walther Cancer Institute, Indiana University School of Medicine, Indianapolis, IN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1053\/shem.2000.0370003"},{"key":"R2","unstructured":"Slichter SJ: Optimizing platelet transfusions in chronically thrombocytopenic patients. Semin Hematol 35:269,1998\u2013278,"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1995.35695288769.x"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1519"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.707"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.5.1141.1141"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.10.2585"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.715"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.11.2063"},{"key":"R10","unstructured":"Tepler I, Elias L, Smith JW, et al: A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87:3607,1996\u20133614,"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.11.3368"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1038\/369533a0"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.23.11104"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1038\/369568a0"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199702063360603"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-9-199705010-00001"},{"key":"R17","unstructured":"Basser RL, Rasko JEJ, Clarke K, et al: Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 89:3118,1997\u20133128,"},{"key":"R18","unstructured":"Vadhan-Raj S, Patel S, Broxmeyer HE, et al: Phase I\u2013II investigation of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I). Blood 88:448a,1996,  (suppl 1, abstr 1779)"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.8.2530"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al: Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 132:364,2000\u2013368,","DOI":"10.7326\/0003-4819-132-5-200003070-00005"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199806000-00025"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107183250305"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199106203242504"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.8.2859.bloodjournal8882859"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1002\/stem.140330"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.8.2998.2998_2998_3006"},{"key":"R29","unstructured":"Nagasawa T, Osada M, Komero T, et al: In vitro and in vivo deprivation of thrombopoietin induces megakaryocytic apoptosis and regulates platelet production. Exp Hematol 25:897,1997,  (abstr 591)"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2234"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2003.08.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:30:29Z","timestamp":1653510629000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2003.08.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,15]]},"references-count":28,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2003,8,15]]}},"alternative-id":["10.1200\/JCO.2003.08.003"],"URL":"https:\/\/doi.org\/10.1200\/jco.2003.08.003","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8,15]]}}}